Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England ...

Researchers have discovered that tirzepatide and semaglutide impact energy metabolism in distinct ways. New animal research ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Starting in 2022, increased demand led to shortages of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy, as well as tirzepatide injections Zepbound and Mounjaro ...